Skip to main content
Edesa Biotech, Inc. logo

Edesa Biotech, Inc. — Investor Relations & Filings

Ticker · EDSA ISIN · CA27966L1085 US Manufacturing
Open in API
Filings indexed 699 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country US United States of America
Listing US EDSA

About Edesa Biotech, Inc.

https://www.edesabiotech.com/

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. The company develops host-directed therapeutics as alternatives to conventional treatments like steroids and JAK inhibitors. Its clinical pipeline targets various conditions, including a significant program for Acute Respiratory Distress Syndrome (ARDS), which has demonstrated clinically significant improvements in survival and recovery. Edesa also develops therapies for dermatological and anorectal conditions, with the goal of addressing unmet medical needs in patients with acute and chronic diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a U.S. SEC Form 8-K (“Current Report”) filed under Section 13 or 15(d) of the Securities Exchange Act of 1934 reporting “Item 8.01 Other Events.” It is a regulatory current report that does not itself constitute a financial report (10-K, IR, etc.) nor an earnings release or proxy solicitation. It is a general SEC disclosure filing, so it falls under the fallback category of Regulatory Filings (RNS).
2026-06-05 English
S-8
Regulatory Filings Classification · 10% confidence The document is a Form S-8 registration statement filed with the SEC under the Securities Act of 1933, relating to the registration of additional shares under an equity incentive plan. This is a securities regulatory filing that does not fit into any of the specific report or announcement categories (e.g., annual report, earnings release, proxy statement, M&A, etc.). Therefore, it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-29 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K reporting Items 5.02 (director departures/elections and compensatory arrangements) and 5.07 (submission of matters to a vote of security holders) and provides detailed voting results at the 2026 Annual General and Special Meeting of Edesa Biotech. The presence of proposals voted on, vote tallies (for, against, abstain, broker non-votes), and official approval outcomes clearly identifies this as a declaration of voting results. Therefore, it matches the DVA category.
2026-05-29 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically Item 5.02 covering appointment/election of a senior officer and changes to his compensatory arrangements. This fits the category for announcements of changes in the company’s board of directors or senior management. Therefore, it should be classified as Board/Management Information (MANG).
2026-05-15 English
FORM 10-Q
Interim / Quarterly Report Q2 2026
2026-05-14 English
FORM 8-K
Regulatory Filings Classification · 87% confidence The document is a SEC Form 8-K “Current Report” filed under Sections 13/15(d), noting the attachment of an earnings press release as an exhibit. It does not contain the full financial data itself but serves as a regulatory filing notifying the market and SEC. There is no specific category for an 8-K in our taxonomy, so it falls under the fallback “Regulatory Filings (RNS).”
2026-05-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.